High-grade and hormone-treated prostate cancer express high levels of thymidylate synthase

BJU International

Volumn 98, Issue 1, 2006, Pages 197-200

  Inoue, Takahiro ^a   Segawa, Takehiko ^a   Shiraishi, Taizo ^b   Yamada, Tomomi ^c   Kinukawa, Naoko ^c   Yoshida, Toru ^a   Toda, Yoshinobu ^a   Shimizu, Yosuke ^a   Nakamura, Eijiro ^a   Kinoshita, Hidefumi ^d   Kamoto, Toshiyuki ^a   Ogawa, Osamu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b MIE UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

^d KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Dihydropyrimidine dehydrogenase; Prostate cancer; Thymidylate synthase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; HORMONE; THYMIDYLATE SYNTHASE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER HORMONE THERAPY; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DIHYDROURACIL DEHYDROGENASE (NADP); HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; THYMIDYLATE SYNTHASE;

EID: 33745089407     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06219.x     Document Type: Article

References (22)

1. Segawa T Ogawa O Merseburger A et al. Definition of gene expression alterations associated with androgen independent prostate cancer cells and evaluation of MCM2 protein in prostate carcinogenesis. J Urol 2003 169: 55 Abstract
2. Longley DB Harkin DP Johnson PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003 3: 330 8
3. Kuniyasu T Nakamura T Tabuchi Y Kuroda Y. Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness. Cancer 1998 83: 1300 6
4. Paradiso A Simone G Petroni S et al. Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 2000 82: 560 7
5. Johnston PG Lenz HJ Leichman CG et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995 55: 1407 12
6. Atkins JN Muss HB Case D et al. High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association. Am J Clin Oncol 1991 14: 526 9
7. Kuzel TM Tallman MS Shevrin D et al. A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study. Cancer 1993 72: 1965 8
8. Hansen R Moynihan T Beatty P et al. Continuous systemic 5-fluorouracil infusion in refractory prostatic cancer. Urology 1991 37: 358 61
9. Kuriyama M Takahashi Y Sahashi M et al. Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. Jpn J Clin Oncol 2001 31: 18 24
10. Khan MA Carducci MA Partin AW. The evolving role of docetaxel in the management of androgen independent prostate cancer. J Urol 2003 170: 1709 16
11. Fischel JL Ferrero JM Formento P et al. Taxotere-5′-deoxy-5- fluorouridine combination on hormone-refractory human prostate cancer cells. Anticancer Drugs 2005 16: 309 16
12. Inoue T Segawa T Shiraishi T et al. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 2005 66: 332 7
13. Inoue T Hioki T Hayashi N Takahashi S Shirai T Sugimura Y. Preoperative predictors of cancerous involvement of the neurovascular bundles in patients with localized prostate cancer. Int J Urol 2002 9: 47 53
14. Kononen J Bubendorf L Kallioniemi A et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998 4: 844 7
15. Bubendorf L Nocito A Moch H Sauter G. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 2001 195: 72 9
16. Torhorst J Bucher C Kononen J et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001 159: 2249 56
17. Yamachika T Nakanishi H Inada K et al. A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 1998 82: 70 7
18. Miyamoto S Boku N Ohtsu A et al. Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group S-1 for Gastric Cancer. Int J Oncol 2000 17: 653 8
19. Fukushima M Morita M Ikeda K Nagayama S. Population study of expression of thymidyalte synthase and dihydropyrimidine dehydrogenase in patients with solid tumors. Int J Mol Med 2003 12: 839 44
20. Latil A Bieche I Chêne L et al. Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior. Clin Cancer Res 2003 9: 5477 85
21. Miyoshi Y Uemura H Ishiguro H et al. Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer. Prostate Cancer Prostatic Dis 2005 8: 260 5
22. Sergeeva MV Cathers BE. Cellular transformation of the investigational new anticancer drug NB1011, a phoshoramidate of 5-(2-bromovinyl)-2′- deoxyuridine, results in modification of cellular proteins not DNA. Biochem Pharmacol 2003 65: 823 31